What are the latest CRISPR gene editing developments?

CRISPR gene editing is advancing at a remarkable pace in 2025, with breakthroughs spanning clinical therapeutics, agricultural applications, and next-generation base editing technologies that are fundamentally reshaping what's possible in precision medicine and beyond.

The most significant clinical momentum continues to build around in vivo CRISPR therapies — treatments delivered directly into the body rather than requiring cells to be edited outside a patient. Intellia Therapeutics has been pushing forward with its NTLA-2002 program targeting hereditary angioedema, with recent trial data showing durable reductions in attack frequency after a single infusion. Meanwhile, The Broad Institute has continued publishing research on prime editing, a more precise cousin of standard CRISPR that can rewrite specific DNA "letters" without creating double-strand breaks — reducing the risk of unintended genomic disruptions. Their work is increasingly demonstrating that prime editing can correct a broader swath of disease-causing mutations than previously thought.

On the agricultural and environmental front, CRISPR applications are gaining regulatory traction. The FDA and USDA have been streamlining pathways for CRISPR-edited crops that don't incorporate foreign DNA, treating them more like conventional breeding. Concurrently, researchers at UC Berkeley — the home institution of Nobel laureate Jennifer Doudna — are exploring CRISPR-based approaches to combat antibiotic-resistant bacteria, using engineered bacteriophages armed with CRISPR systems to selectively destroy pathogenic strains. This "anti-CRISPR" arms race between bacteria and phages is yielding fascinating biological insights with real therapeutic potential.

The delivery problem remains the field's most critical bottleneck. Lipid nanoparticles have become the dominant vehicle for getting CRISPR components into cells, but reaching tissues beyond the liver at therapeutic doses remains challenging. Expect the next wave of headlines to focus on engineered viral vectors and novel nanoparticle chemistries designed to unlock lung, muscle, and central nervous system targeting — capabilities that would dramatically expand the range of treatable diseases. The race to crack non-liver delivery is arguably the defining competition in biotech right now, and whichever platform wins will likely define the next decade of genetic medicine.

— Pulse